Rifampin

( DrugBank: Rifampin / KEGG DRUG: Rifampin, Rifampicin sodium )


5 diseases
IDDisease name (Link within this page)Number of trials
6Parkinson disease1
13Multiple sclerosis/Neuromyelitis optica1
84Sarcoidosis2
IDDisease name (Link within this page)Number of trials
86Pulmonary arterial hypertension1
299Cystic fibrosis7

6. Parkinson disease


Clinical trials : 2,817 / Drugs : 2,606 - (DrugBank : 348) / Drug target genes : 185 - Drug target pathways : 205 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

13. Multiple sclerosis/Neuromyelitis optica


Clinical trials : 3,898 / Drugs : 2,785 - (DrugBank : 360) / Drug target genes : 265 - Drug target pathways : 239 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

84. Sarcoidosis


Clinical trials : 196 / Drugs : 261 - (DrugBank : 78) / Drug target genes : 73 - Drug target pathways : 183 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

86. Pulmonary arterial hypertension


Clinical trials : 1,348 / Drugs : 828 - (DrugBank : 133) / Drug target genes : 82 - Drug target pathways : 197 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

299. Cystic fibrosis


Clinical trials : 1,885 / Drugs : 1,782 - (DrugBank : 252) / Drug target genes : 110 - Drug target pathways : 190 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries